Clinical validation study of dried blood spot for determining everolimus concentration in patients with cancer.

ABSTRACT:

Purpose

Everolimus treatment is seriously hampered by its toxicity profile. As a relationship between everolimus exposure and effectiveness and toxicity has been established, early and ongoing concentration measurement can be key to individualize the dose and optimize treatment outcomes. Dried blood spot (DBS) facilitates sampling at a patients' home and thereby eases dose individualization. The aim of this study is to determine the agreement and predictive performance of DBS compared to whole blood (WB) to measure everolimus concentrations in cancer patients.

Methods

Paired DBS and WB samples were collected in 22 cancer patients treated with everolimus and analyzed using UPLC-MS/MS. Bland-Altman and Passing-Bablok analysis were used to determine method agreement. Limits of

SUBMITTER: Willemsen AECAB 

PROVIDER: S-EPMC5849667 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature